| Search Immortality Topics: |
Posted: April 9, 2024 at 1:01 pm
Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024.
See the original post here:
QIAGEN N.V. to release results for Q1 2024 and hold webcast
Recommendation and review posted by G. Smith
Posted: April 9, 2024 at 1:01 pm
See the original post here:
Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting
Recommendation and review posted by G. Smith
Posted: April 9, 2024 at 1:01 pm
Article 223-16 of general regulation of French Autorité des Marchés Financiers
Continue reading here:
Monthly information related to total number of voting rights and shares composing the share capital – March 29, 2024
Recommendation and review posted by G. Smith
Posted: April 9, 2024 at 1:01 pm
- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status
View original post here:
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head...
Recommendation and review posted by G. Smith
Posted: April 9, 2024 at 1:01 pm
- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibition than either treatment alone -
View original post here:
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
Recommendation and review posted by G. Smith
Posted: April 9, 2024 at 1:01 pm
Non-Clinical Poster Data Support the Use of Dual Antigen Approach to Enhance Anti-Tumor Activity Non-Clinical Poster Data Support the Use of Dual Antigen Approach to Enhance Anti-Tumor Activity
Recommendation and review posted by G. Smith
